1. Home
  2. MHD vs AUTL Comparison

MHD vs AUTL Comparison

Compare MHD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniHoldings Fund Inc.

MHD

Blackrock MuniHoldings Fund Inc.

HOLD

Current Price

$11.62

Market Cap

604.8M

Sector

Finance

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$2.07

Market Cap

532.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHD
AUTL
Founded
N/A
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
604.8M
532.3M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
MHD
AUTL
Price
$11.62
$2.07
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
281.0K
2.0M
Earning Date
01-01-0001
05-14-2026
Dividend Yield
4.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
N/A
$80.32
Revenue Next Year
N/A
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$10.99
$1.18
52 Week High
$12.08
$2.50

Technical Indicators

Market Signals
Indicator
MHD
AUTL
Relative Strength Index (RSI) 45.88 73.83
Support Level $11.40 $1.31
Resistance Level $11.86 N/A
Average True Range (ATR) 0.10 0.13
MACD 0.01 0.07
Stochastic Oscillator 58.31 96.94

Price Performance

Historical Comparison
MHD
AUTL

About MHD Blackrock MuniHoldings Fund Inc.

Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: